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Abstract
Indigenous Australian women have much higher incidence of cervical cancer compared to
non-Indigenous women. Despite an organised cervical screening program introduced 25
years ago, a paucity of Indigenous-identified data in Pap Smear Registers remains. Prev-
alence of cervical abnormalities detected among the screened Indigenous population has
not previously been reported. We conducted a retrospective cohort study of population-
based linked health records for 1,334,795 female Queensland residents aged 20–69
years who had one or more Pap smears during 2000–2011; from linked hospital records
23,483 were identified as Indigenous. Prevalence was calculated separately for Indige-
nous and non-Indigenous women, for cytology-detected low-grade (cLGA) and high-
grade abnormalities (cHGA), and histologically confirmed high-grade abnormalities
(hHGA). Odds ratios (OR) were estimated from logistic regression analysis. In 2010–2011
the prevalence of hHGA among Indigenous women (16.6 per 1000 women screened,
95% confidence interval [CI] 14.6–18.9) was twice that of non-Indigenous women (7.5 per
1000 women screened, CI 7.3–7.7). Adjusted for age, area-level disadvantage and place
of residence, Indigenous women had higher prevalence of cLGA (OR 1.4, CI 1.3–1.4),
cHGA (OR 2.2, CI 2.1–2.3) and hHGA (OR 2.0, CI 1.9–2.1). Our findings show that Indige-
nous women recorded on the Pap Smear Register have much higher prevalence for
cLGA, cHGA and hHGA compared to non-Indigenous women. The renewed cervical
screening program, to be implemented in 2017, offers opportunities to reduce the burden
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of abnormalities and invasive cancer among Indigenous women and address long-stand-
ing data deficiencies.
Introduction
The Australian National Cervical Screening Program (NCSP), introduced in 1991, recom-
mends routine two-year screening by Papanicolau (Pap) smears for women aged 20 to 69 years
who have ever been sexually active, regardless of human papillomavirus (HPV) vaccination
status, ethnicity, sexual orientation or religion [1]. The major aim of the NCSP is to detect and
treat cervical abnormalities prior to progression to invasive cervical cancer. A national system
of state-based Pap Smear Registers (PSR) systematically records results of cervical screening,
performs a recall and reminder function for women and their primary care providers, and a
safety net function for follow up of screen-detected abnormalities. PSRs provide data for
national reporting on screening participation, prevalence of abnormalities, outcomes after an
abnormal Pap smear and other program quality indicators [2].
Low-grade abnormalities (LGA), indicated by a cytological diagnosis of a low-grade squa-
mous intraepithelial lesion on a Pap smear, are common among young women and usually
represent a cellular response to acute HPV infection [3]. Most LGAs resolve without treatment
because the infection is cleared; a repeat smear after 6–12 months is currently recommended
(unless a woman is aged over 30 years without a recent normal screening history), because per-
sistent infection increases the risk of a high-grade abnormality being present [4–6]. High-grade
abnormalities (HGA), as indicated by a cytological detection of a high-grade squamous intrae-
pithelial lesion or a glandular abnormality, can indicate a true precancerous abnormality of the
cervix (cervical intraepithelial neoplasia [CIN] grade 3 or adenocarcinoma in situ) or possibly
a CIN grade 2 lesion, which is a diagnostic classification that includes both florid low-grade dis-
ease and grade 3 disease [7]. Since it is not possible to determine which high-grade lesions will
eventually progress to cancer and which will resolve, all are investigated and treatment of con-
firmed high grade lesions is recommended by the current National Health and Medical
Research Council guidelines (p.53) [4,8]. Prompt follow-up of cytology predicted HGAs by
colposcopy and biopsy is required to confirm the diagnosis prior to treating the lesion [4].
Aboriginal and Torres Strait Islander women, hereafter respectfully referred to as Indige-
nous Australian women, have cervical cancer incidence and mortality rates two and four times
higher than their non-Indigenous counterparts [9,10]. The NCSP cannot report on screening
participation, abnormalities or outcomes for Indigenous women because pathology report
forms (the source of information for PSRs) do not include Indigenous status [10–12].
Recently, using record-linkage methods [13], we have reported lower cervical screening par-
ticipation rates among Indigenous women compared to non-Indigenous women in Queens-
land [14]. We report for the first time the prevalence of cervical abnormalities for Indigenous
women compared to non-Indigenous women participating in cervical screening in Queens-




The detailed data extraction and linkage methods have been described previously [13]. Briefly,
the dataset included linked records from the Queensland PSR and the Queensland Hospital
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Admitted Patient Data Collections (QHAPDC). The Queensland PSR was used to identify
women resident in Queensland aged 20–69 years (at the time of testing) who had a Pap smear
between February 1999 (the start of the Queensland PSR) and December 2011, and had not
opted to be excluded from the Queensland PSR. Variables obtained from the Queensland PSR
included: date of birth (mm/yyyy); place of residence (suburb and postcode); test date; type
(cytology or histology); and result. An Indigenous identifier was assigned to the PSR cohort by
linking to a QHAPDC extract of women aged 20–69 years who had ever been identified as
Indigenous when admitted to a Queensland public hospital during 1995–2011. The QHAPDC
has reasonably high accuracy of Indigenous status: in 2011/12, 87% (95% CI 84–91) of Indige-
nous inpatients were correctly identified as Indigenous in hospital records (compared to self-
identification) [15]. Women who linked to at least one QHAPDC record were identified as
Indigenous if at least 50% of their QHAPDC records identified them as such [13,16]. Those
who did not match to at least one QHAPDC extract record, or had fewer than 50% of their
QHAPDC records identified as Indigenous, were assumed to be non-Indigenous. Women were
excluded from the study if they had insufficient details to determine the statistical local area
(SLA) of residence within Queensland for at least one Pap smear.
Outcome Measures
Abnormal Pap smear results were categorised according to the Australian Modified Bethesda
System 2004 as: low-grade abnormality (LGA: possible or definitive low-grade squamous
intraepithelial lesion detected at cytology [includes previous terminology of atypical squamous
cells of undetermined significance]); or high-grade abnormality (HGA: prediction of CIN 2 or
higher, adenocarcinoma in situ, or invasive cancers [includes previous terminology of atypical
squamous cells, possible high-grade lesion]), consistent with current national reporting [4].
Cytology-detected LGA and HGA are hereafter referred to as cLGA and cHGA, respectively, to
distinguish them from histologically confirmed HGA (hHGA). We categorised women as hav-
ing an hHGA if there was a record of hHGA within six months after the date of a Pap smear.
Women with an HGA histology report who had not had a cytology test within the previous six
months were excluded because these tests may have resulted from investigations other than
cervical screening.
Location of residence based on suburb and postcode at the time of Pap smear was mapped
to the 2011 SLA boundaries. If the address information for a specific Pap smear was insufficient
to determine SLA, then information from the closest adjacent record for the same woman was
used. SLAs were grouped into five categories from major city to very remote [17]. We assigned
an area-based measure of socioeconomic disadvantage to each woman based on the SLA of
place of residence using the Index of Relative Socio-Economic Advantage and Disadvantage,
with Queensland population-based quintiles from most disadvantaged to most affluent [18].
Statistical analyses. Demographic characteristics are presented as medians (with inter-
quartile ranges [IQR]) for non-normally distributed continuous variables and as frequencies
and percentages for categorical variables. Proportions for different groups of women were
compared using chi-squared tests. Prevalence of hHGA was determined by dividing the num-
ber of hHGA in each two-year calendar period (2000–2001 to 2010–2011) by the number of
women who were screened in the corresponding two-year period and directly age-standardised
based on the 2001 Australian Estimated Resident Population and expressed per 1000 women
[19]. Simple linear regression was used to graphically present the association of age-standard-
ised hHGA prevalence and time period stratified by Indigenous status.
Logistic regression was used to quantify the association (as odds ratios) between independent
variables of interest and the prevalence of each of cLGA, cHGA and hHGA. The regression
Cervical Abnormalities among Indigenous Australian Women
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models for each outcome included five a priori independent categorical variables of interest (the
‘main effects’model): Indigenous status; age at time of test, in age-groups of 20–29, 30–39, 40–
49 (reference category), 50–59 and 60–69 years; two-year calendar periods from 2000–2001 (ref-
erence category) to 2010–2011; place of residence (inner regional as the reference category); and
disadvantage quintiles (quintile 3 as the reference category). An interaction between each inde-
pendent variable and Indigenous status was assessed, but these were not included in the final
models because inclusion of the individual interaction terms did not change the estimates for
the other a priori variables substantially. To examine if prevalence of abnormalities within each
age-group was changing over time, we fitted separate logistic models for each age-group for
cLGA and hHGA, including two-year calendar periods as an ordinal variable and Indigenous
status, area-level disadvantage and place of residence. We assessed if temporal trends differed by
Indigenous status by fitting an interaction term.
To assess whether hHGA was more common for women who had not previously had a Pap
smear, we selected women aged 30–69 years who had a Pap smear in 2010–2011 and dichoto-
mised their screening history into ‘yes previous screen’ or ‘no previous screen’ using a ten-year
look-back period (2000–2009). Of these women, we determined how many had an hHGA up
to six months after their Pap smear in 2010–2011.
Given the non-independence of multiple tests carried out for each woman, we accounted
for clustering (i.e. treating each woman as a cluster) in the logistic models and assessed the
overall model fit. Because the likelihood ratio test was not appropriate when accounting for
clustering, we used the Wald chi-squared test to determine overall significance of each covari-
ate and interaction term. Joint chi-squared tests were used to assess the contribution of each
variable to model fit, and the Z test to assess the significance of individual coefficients within
the logistic model.
All analyses were conducted using Stata (Version 14.0; Stata Corporation, College Station,
TX) [20].
The Human Research Ethics Committees (HREC) of Queensland Health (Far North
Queensland HREC HREC/15/QCH/19-957), the Northern Territory Department of Health &
Menzies School of Health Research (HOMER-2012-1737) and Charles Darwin University
(H12093) approved the study along with the Queensland Research Linkage Group, data custo-
dians, and director general of Queensland Health to access and link records. The research team
received a de-identified linked dataset and therefore was unable to obtain individual consent
from participants. This process was approved by the aforementioned ethics committees.
Results
We excluded 1545 women with conflicting dates of birth, 3174 women with missing address
details (a total of 11,072 Pap tests) and 518 women with hHGA only. Our final cohort included
1,334,795 women with 4,565,250 Pap smears from 2000–2011. There were 26,829 Indigenous
women (2.0%) identified in the PSR cohort with 87,372 Pap smears. The median number of
Pap smears per woman was similar for Indigenous and non-Indigenous women (3, IQR 1–5).
Similar proportions of Indigenous and non-Indigenous women had only one (26.9% vs
26.6%), two or three (35.4% vs 30.9%) and four or more (37.7% vs 42.4%) Pap smears during
the study period. The demographic details of women at their first recorded Pap smear are sum-
marised in Table 1. Indigenous women compared to non-Indigenous women were more likely
to be younger (median age 34, IQR 27–43 vs 40, IQR 30–50), live outside major cities and live
in less affluent areas.
The proportions of abnormal tests by socio-demographic variables for Indigenous and non-
Indigenous women are shown in Table 2. Greater proportions of tests for Indigenous women
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compared with non-Indigenous women had cLGA and cHGA (p<0.001) overall and this was
consistent by age-group, area-level disadvantage and place of residence.
The odds of Indigenous women having cLGA (OR 1.7, 95% CI 1.6–1.7), cHGA (OR 2.8, CI
2.7–3.0) and hHGA (OR 2.6, CI 2.5–2.8) were higher than non-Indigenous women after
adjusting only for year of Pap smear. The odds remained higher when adjusted further for
area-level disadvantage, place of residence and age-group, for example, cLGA OR 1.4, CI 1.3–
1.4 (Table 3).
The prevalence of cLGA decreased after 2005; was lower for older than younger women, but
was not associated with area-level disadvantage. Compared to women in inner regional areas,
women living in all other areas had a higher prevalence of cLGA. For all women, cLGA preva-
lence significantly decreased over time in all age-groups (Table 4). The prevalence of cHGA
increased over time, was lower in the most affluent area, and for older women, but was higher
in outer regional, remote and very remote areas (Table 3).
The prevalence of hHGA was higher among Indigenous (16.5 per 1000 women screened, CI
13.9–19.5) than non-Indigenous women (7.3 per 1000 women screened, CI 7.1–7.6), in 2000–
2001 and remained relatively constant in both groups up to 2010–2011 (16.6 per 1000 women
screened, CI 14.6–18.9 and 7.5 per 1000 women screened, CI 7.3–7.7, respectively). Prevalence
was higher for Indigenous women in each age-group (Fig 1). In the 20–29 year age-group,
prevalence of hHGA increased over time for Indigenous women only and multivariable analy-
sis confirmed this was a statistically significant trend (Table 4). There were no significant
changes in prevalence of hHGA over time for other age-groups among Indigenous women.
Among non-Indigenous women, hHGA prevalence decreased significantly in 40–69 year olds.
Table 1. Characteristics of Indigenous and non-Indigenous women at their first recorded Pap smear.
Indigenous Non-Indigenous pa
Variables N % N %
Totals 26,829 2.0 1,307,966 98.0
Age group (years)
20–29 13,104 48.8 476,371 36.4
30–39 6790 25.3 388,932 25.9
40–49 4107 15.3 258,661 19.8
50–59 1982 7.4 158,310 12.1
60–69 846 3.2 75,692 5.8 <0.001
Area-level disadvantage
Q1 (most disadvantaged) 7358 27.4 148,552 11.4
Q2 9281 34.6 285,133 21.8
Q3 4877 18.2 301,630 23.1
Q4 4090 15.2 326,672 25.0
Q5 (most afﬂuent) 1223 4.6 245,979 18.8 <0.001
Place of residence
Major city 6700 25.0 812,894 62.2
Inner regional 4259 15.9 252,875 19.3
Outer regional 10,593 39.5 218,651 16.7
Remote 2129 7.9 14,611 1.1
Very remote 3148 11.7 8935 0.7 <0.001
aChi-squared test of association for categorical variables
doi:10.1371/journal.pone.0150473.t001
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In 2010–2011, 548,549 women aged 30–69 years had a Pap smear, of whom 1.6% were
Indigenous. hHGA was more common among women without a Pap smear history (unad-
justed prevalence Indigenous: 36.6 per 1000 women without and 11.3 per 1000 with screening
history; non-Indigenous: 10.7 per 1000 without and 4.5 per 1000 with screening history).
We carried out a sensitivity analysis by re-running all models and estimating hHGA preva-
lence by excluding cervical cancer in the definition of the outcome variable; there were no dif-
ferences in these and the main results for the prevalence of hHGA (comparison data not
shown). We also calculated a histology detection rate, based on the number of HGAs reported
by histology, using the method as reported by the Australian Institute of Health and Welfare
[21]: the detection rate was 23 and 9 per 1000 women screened in 2011 for Indigenous women
and non-Indigenous women, respectively.
Discussion
Indigenous women had markedly higher prevalence of cytology-detected and histology-con-
firmed cervical abnormalities than non-Indigenous women. The prevalence of cHGA increased
over time for Indigenous women only. Prevalence of cLGA decreased over time for both groups
of women.
Table 2. Demographic characteristics of Indigenous and non-Indigenous women’s Pap smears by abnormality, 2000–2011.
Indigenous Non-Indigenous
Variables N % cLGA % cHGA N % cLGA % cHGAa
No. Pap smears 87,372 6.6 3.2 4,477,878 4.3 1.2
Age group (years)
20–24 15,485 13.4 5.7 481,149 10.9 2.3
25–29 15,897 8.5 5.2 554,668 6.8 2.2
30–39 26,854 6.0 3.1 1,193,327 4.3 1.4
40–49 16,659 4.7 2.1 1,080,806 3.7 0.7
50–59 8619 3.4 1.3 765,180 2.8 0.5
60–69 3 858 3.4 1.5 402,748 2.0 0.5
Area-level disadvantage
Q1 24,546 7.2 3.6 501,561 4.5 1.2
Q2 30,114 7.0 3.7 996,147 4.6 1.3
Q3 15,363 7.2 3.3 1,042,366 4.6 1.2
Q4 13,164 7.4 3.6 1,080,243 4.8 1.2
Q5 (most afﬂuent) 4185 6.9 2.7 857,561 4.8 1.1
Place of residence
Major cities 21,334 7.0 3.1 2,745,136 4.8 1.1
Inner regional 13,503 7.1 3.4 895,540 4.2 1.2
Outer regional 35,060 7.0 3.7 761,111 4.9 1.3
Remote 6609 8.4 4.4 46,932 5.0 1.6
Very remote 10,866 7.0 3.3 29,159 4.9 1.7
Notes:
1. Table 2 shows the proportion of abnormal results from the total number of tests by Indigenous status (excluding tests that were taken in the same year
with the same result).
2. cLGA: Cytology detected low-grade abnormality; cHGA: cytology detected high-grade abnormality.
a Statistically signiﬁcant chi-squared test for association, p<0.001 comparing the proportion of abnormal Pap smears among Indigenous women and the
proportion of abnormal Pap smears among non-Indigenous women.
doi:10.1371/journal.pone.0150473.t002
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We were able to identify Indigenous women in the PSR only if women had been a public
hospital inpatient between 1995 and 2011 [13]. Women admitted to hospital may differ from
those who were not. Indirect evidence suggests that almost all Indigenous women in the age-
range for our study would have been admitted to a public hospital over the 17 year period that
we used to identify Indigenous women [13], so it is likely that our results apply to almost all
screening women. Queensland has the second highest proportion of Indigenous people in its
population and they have widely varied geographic and socioeconomic characteristics. There-
fore, it is probable that the results for Queensland be applicable to the broader Australian
Indigenous population.
The availability of individual-level PSR data facilitated a more precise method for estimating
the prevalence of hHGA than reported previously [21]. This previous method calculated hHGA
Table 3. Association of Indigenous status, calendar period, place of residence, area-level disadvantage and age with risk of cytology detected
low-grade abnormalities and cytological and histological high-grade abnormalities including cervical cancer.
cLGA cHGA hHGA
Variables Adjusted ORs (95% CI) Adjusted ORs (95% CI) Adjusted ORs (95% CI)
Indigenous status
Indigenous women 1.38 (1.33–1.43) 2.16 (2.05–2.27) 1.98 (1.87–2.10)
Year
2000–2001 1.00 1.00 1.00
2002–2003 0.99 (0.98–1.01) 1.04 (1.00–1.07) 1.07 (1.03–1.11)
2004–2005 0.99 (0.97–1.00) 1.19 (1.15–1.23) 0.98 (0.94–1.01)
2006–2007 0.82 (0.80–0.83) 1.23 (1.19–1.287) 0.92 (0.88–0.96)
2008–2009 0.65 (0.64–0.66) 1.19 (1.15–1.23) 0.94 (0.91–0.98)
2010–2011 0.52 (0.57–0.59) 1.25 (1.25–1.33) 1.02 (0.98–1.06)
Area-level disadvantage
Q1 1.00 (0.98–1.02) 1.06 (1.02–1.10) 1.04 (1.00–1.09)
Q2 1.01 (0.99–1.03) 1.06 (1.03–1.09) 1.08 (1.04–1.12)
Q3 1.00 1.00 1.00
Q4 1.01 (0.99–1.03) 1.02 (0.99–1.05) 0.97 (0.94–1.00)
Q5 (most afﬂuent) 1.00 (0.98–1.02) 0.90 (0.87–0.93) 0.94 (0.88–1.02)
Place of residence
Major city 1.09 (1.08–1.11) 0.99 (0.96–1.02) 1.02 (0.98–1.05)
Inner regional 1.00 1.00 1.00
Outer regional 1.12 (1.10–1.14) 1.09 (1.05–1.12) 1.07 (1.03–1.11)
Remote 1.13 (1.08–1.18) 1.24 (1.15–1.34) 1.18 (1.08–1.30)
Very remote 1.09 (1.04–1.16) 1.11 (1.02–1.22) 1.04(0.93–1.16)
Age group (years)
20–29 2.53 (2.50–2.57) 3.15 (2.05–2.27) 4.20 (4.05–4.36)
30–39 1.18 (1.16–1.20) 1.87 (1.81–1.92) 2.30 (2.21–2.39)
40–49 1.00 1.00 1.00
50–59 0.75 (0.74–0.77) 0.70 (0.67–0.73) 0.53 (0.50–0.56)
60–69 0.52 (0.50–0.53) 0.59 (0.56–0.63) 0.42 (0.39–0.46)
Notes:
1. Binary logistic regression model comparing odds of having an abnormality adjusted for all a priori variables in the table. Clustering of Pap smears for
women was accounted for in each model.
2. Table 3 presents OR, Odd Ratios: 95% C.I., 95% Conﬁdence Intervals
3. Each independent variable in the table had overall p<0.001 and each outcome variable (type of abnormality) p<0.001.
doi:10.1371/journal.pone.0150473.t003
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prevalence from aggregated data supplied by PSRs: number of hHGAs (excluding cancer)
divided by the number of women screened. We calculated hHGA prevalence directly for
screened women (i.e. including only hHGA/cervical cancer if there was a record of a recent Pap
smear) using individual-level data. This increased precision in estimating hHGA prevalence in
screened women provides greater validity of our study findings. Differences in estimation meth-
ods mean comparisons with previously published estimates requires some caution [22].
Participation in cervical screening of Indigenous women is significantly less than that of
non-Indigenous women in Queensland, a known risk factor for cervical cancer [14]. Increasing
screening among Indigenous women would likely reduce HGAs. We did not have data about
other risk factors such as persistent HPV infection, lower individual-level socio-economic sta-
tus, lower education level, smoking, possible dietary deficiencies, oral contraception, age at first
intercourse and early and higher parity [23–27]. The prevalence of HPV types 16 and 18 has
previously been reported to be similar for Indigenous and non-Indigenous women and more
recently similar age at sexual debut has been reported [28,29]. Some evidence indicates that
Indigenous women have higher prevalence of other oncogenic HPV types in the 36–40 year
age-group [29]. Indigenous women in this cohort had much higher prevalence of LGAs—a
known marker of productive HPV infection—and hHGAs, of which 50–60% are caused by
HPV types 16 and 18 [3,30]. This suggests that a difference in HPV infection patterns may
exist. Young Indigenous women have higher smoking rates [2], lower age at parity and higher
fertility rates [31], less oral contraceptive use [29] and are more likely to live in areas of disad-
vantage [2]. It is crucial to understand the possible role of these factors in the increased risk of
HGAs developing (or not regressing) among Indigenous women.
The Australian Government has announced changes to the current NCSP which will shift
to a new program (the ‘Renewal’) in May 2017 using primary HPV testing every five years for
women aged 25–74 years [32,33]. Starting screening at age 25 is consistent with international
reports showing that screening and treatment of HGAs below the age of 25 is not effective at
preventing cancer [34], and will occur in the context of the significant decline in high-grade
lesions in 20–24 year olds following the 2007 introduction of the national HPV vaccination
program in Australia [10,35]. Given our findings it is timely and important that the Renewal
helps address the needs of Indigenous women. High prevalence of HGAs among Indigenous
women has previously been reported among Indigenous women in remote areas [22]. Increas-
ing the uptake of HPV vaccination for Indigenous children must be a priority. Although some
evidence indicates coverage and/or dose completion rates for Indigenous female adolescents
Table 4. Time trends in prevalence of cytology low-grade and histologically confirmed high-grade abnormalities by age-group, 2000–2011.
cLGA hHGA
Age-groupa All womenb Indigenous Non-Indigenous
20–29 0.94 (0.94–0.94) 1.07 (1.03–1.12) 1.00 (0.99–1.01)
30–39 0.89 (0.88–0.85) 0.99 (0.93–1.05) 0.99 (0.98–1.01)
40–49 0.84 (0.84–0.85) 1.03 (0.93–1.14) 0.96 (0.94–0.98)
50–59 0.81 (0.81–0.82) 0.92 (0.76–1.12) 0.94 (0.91–0.97)
60–69 0.81 (0.80–0.82) 0.84 (0.68–1.02) 0.91 (0.87–0.96)
Notes:
1. Table 4 reports OR (Odd Ratios) for a two-year increase in time; followed by 95% CI (Conﬁdence Intervals).
2. cLGA: Cytology detected low-grade abnormality; cHGA: cytology detected high-grade abnormality.
aeach model included Indigenous status, area-level disadvantage and place of residence and an interaction term for Indigenous status and year.
bORs were similar for Indigenous and non-Indigenous women for cLGAs over time and therefore have been presented for all women combined.
doi:10.1371/journal.pone.0150473.t004
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Fig 1. Prevalence of histologically confirmed high-grade abnormalities per 1000 women screened, by
age-group and Indigenous status, 2000–2011.
doi:10.1371/journal.pone.0150473.g001
Cervical Abnormalities among Indigenous Australian Women
PLOSONE | DOI:10.1371/journal.pone.0150473 April 11, 2016 9 / 12
during the catch-up phase were lower than for non-Indigenous female adolescents [36], reas-
suringly, early vaccination program outcomes in terms of falls in presentations for anogenital
warts (caused by HPV types also included in the vaccine) have been similar for 15–25 year old
Indigenous and non-Indigenous females [37]. Over the longer term, it is hoped that current
school-based routine HPV vaccination, which now includes boys as well as girls, will encourage
relatively high ongoing coverage overall and that this mode of delivery will reduce inequities in
outcomes for Indigenous women.
The Renewal will provide the option of self-collection of HPV samples for under-screened
and never-screened women, which is supported by international evidence that self-collection
can increase screening among these groups [38]. Other opportunities to increase screening
include an invitation to commence screening at a woman’s 25th birthday using a call-and-recall
system inviting women to rescreen, rather than the current reminder-based screening system.
Possible mediums of invitations could be considered such as using SMS or email or letter and
the inclusion of educational resources and information.
Evidence suggests that there has been some reduction in the incidence of cervical cancer
over time among Indigenous women [9,10,39], indicating that efforts to reduce the burden of
cervical cancer for Indigenous women have been somewhat effective. For over two decades the
NCSP has been unable to report on the impacts of the program for Indigenous Australian
women on a wide range of outcomes [11,12,21]. The Renewal program must take the critical
opportunity to ensure that Indigenous women are able to be recorded in the proposed national
registry. Our study provides benchmark measures giving an opportunity to develop and assess
the effectiveness of interventions designed to increase the number of women who are followed
up for a serious abnormality and reduce the severity of those outcomes.
Internationally, Australia has been at the forefront of cervical cancer prevention. However,
below the surface of this success, Indigenous Australian women carry a disproportionate bur-
den of disease, comparable to many countries without the resources available in Australia. The
Renewal of the cervical screening program provides the opportunity to overcome long standing
data deficiencies and should consider the Indigenous-specific patterns and trends identified in
our study. It is imperative that any major changes to current screening practices prioritise
Indigenous women. Failure to do so will result in further disenfranchisement and disadvantage
of Indigenous women, their families and their communities.
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